Equities Analysts Offer Predictions for TARA FY2028 Earnings

Key Points

• HC Wainwright raised its FY2028 EPS estimate for Protara to ($0.84) from ($1.14), keeps a "Buy" rating and a $27.00 price target, and projects FY2029 EPS of $0.28 and FY2030 EPS of $0.82 (consensus current full-year estimate is ($1.58)).
• Analyst coverage is mixed but skewed positive—one Strong Buy, four Buy and one Sell—leaving an average rating of "Moderate Buy" and an average target price of $24.75.
• Shares trade around $5.32 with a 12‑month range of $2.77–$7.82 and a market cap of ~$293M; institutional investors have recently increased positions while insider Jacqueline Zummo sold 22,598 shares, reducing her stake by ~19%.

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Equities research analysts at HC Wainwright raised their FY2028 EPS estimates for shares of Protara Therapeutics in a research note issued to investors on Wednesday, April 29th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.84) per share for the year, up from their previous estimate of ($1.14). HC Wainwright currently has a "Buy" rating and a $27.00 target price on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($1.58) per share. HC Wainwright also issued estimates for Protara Therapeutics' FY2029 earnings at $0.28 EPS and FY2030 earnings at $0.82 EPS.

A number of other brokerages have also commented on TARA. Weiss Ratings restated a "sell (d-)" rating on shares of Protara Therapeutics in a research note on Tuesday, April 21st. TD Cowen reiterated a "buy" rating on shares of Protara Therapeutics in a research note on Tuesday, March 10th. JPMorgan Chase & Co. began coverage on shares of Protara Therapeutics in a report on Wednesday, March 4th. They issued an "overweight" rating and a $27.00 price target on the stock. Finally, Piper Sandler initiated coverage on shares of Protara Therapeutics in a research note on Wednesday, January 7th. They issued an "overweight" rating and a $24.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $24.75.

Protara Therapeutics Stock Performance

Shares of TARA stock opened at $5.32 on Monday. Protara Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.82. The company has a market capitalization of $292.92 million, a P/E ratio of -4.03 and a beta of 1.53. The stock has a 50 day moving average of $5.43 and a two-hundred day moving average of $5.71.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its earnings results on Tuesday, March 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.03).

Institutional Trading of Protara Therapeutics

Institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Protara Therapeutics during the second quarter worth $53,000. AIGH Capital Management LLC acquired a new stake in shares of Protara Therapeutics in the 1st quarter valued at $8,454,000. Assenagon Asset Management S.A. grew its holdings in shares of Protara Therapeutics by 84.1% in the 1st quarter. Assenagon Asset Management S.A. now owns 567,621 shares of the company's stock worth $2,957,000 after purchasing an additional 259,287 shares during the last quarter. 5AM Venture Management LLC grew its holdings in shares of Protara Therapeutics by 71.2% in the 4th quarter. 5AM Venture Management LLC now owns 1,369,782 shares of the company's stock worth $7,301,000 after purchasing an additional 569,782 shares during the last quarter. Finally, Baker BROS. Advisors LP increased its position in shares of Protara Therapeutics by 81.0% during the 4th quarter. Baker BROS. Advisors LP now owns 971,614 shares of the company's stock worth $5,179,000 after purchasing an additional 434,782 shares in the last quarter. Institutional investors and hedge funds own 38.13% of the company's stock.

Insider Buying and Selling at Protara Therapeutics

In other news, insider Jacqueline Zummo sold 22,598 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total value of $118,865.48. Following the completion of the transaction, the insider directly owned 95,961 shares of the company's stock, valued at approximately $504,754.86. This represents a 19.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 12.50% of the company's stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company's primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body's immune response to target tumor cells. Protara's therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara's lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.